Stevanato Group Earnings Call Highlights High-Value Surge

Stevanato Group Spa ((STVN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Stevanato Group’s latest earnings call struck an upbeat tone, as strong growth in high-value biopharma products and GLP‑1 demand outweighed weakness in the Engineering segment. Management highlighted expanding margins, solid free cash flow despite heavy CapEx, and capacity investments that underpin constructive guidance heading into 2026.

Full-Year Revenue Growth Signals Solid Momentum

Stevanato reported 2025 revenue growth of 9% at constant currency and 7% on a reported basis versus 2024, landing squarely within prior guidance. This performance gives the company a solid base of momentum as it moves into 2026, even with foreign exchange and tariff headwinds in the backdrop.

BDS Outperformance Offsets Engineering Weakness

The Biopharmaceutical & Diagnostic Solutions division delivered double-digit growth for the year and finished Q4 with revenue up 13% at constant currency to EUR 307.1 million. This strength more than offset the drag from the Engineering segment and was a key driver of consolidated results.

High-Value Solutions Power Growth and Margins

Revenue from high-value solutions surged 29% in 2025 and jumped 31% in Q4 to EUR 171 million. These offerings now represent roughly 46% of full-year company revenue and about 49% in Q4, sharply lifting the company’s overall profitability profile.

GLP‑1 Demand Provides a Powerful Tailwind

Products linked to GLP‑1 therapies accounted for roughly 19%–20% of total revenue in 2025 and grew more than 50% year over year. Management expects GLP‑1s to remain a major growth engine, projecting mid-teens percentage growth from this category in 2026.

Margin Expansion Confirms Operating Leverage

Full-year gross profit margin expanded about 160 basis points compared with 2024, reflecting better mix and scale. In Q4, gross margin improved 120 basis points to 30.9%, aided by higher utilization at new facilities and the shift toward high-value products.

Profitability and Adjusted Metrics Show Healthy Q4

In the fourth quarter, net profit reached EUR 47.6 million, or diluted EPS of EUR 0.17, while adjusted net profit was EUR 49.8 million with adjusted diluted EPS of EUR 0.18. Adjusted EBITDA rose 7% to EUR 97.7 million, pushing the adjusted EBITDA margin up 70 basis points to 28.2%.

Positive Free Cash Flow Despite Heavy CapEx

Stevanato generated EUR 286.1 million in operating cash flow during 2025, underpinning its investment cycle. After EUR 294.9 million of capital expenditures, largely directed to growth projects, the company still delivered positive free cash flow of EUR 18.4 million.

Strategic Capacity Investments Expand Global Reach

Management highlighted substantial build-out at Latina, where syringe capacity is ramping and EZ‑fill cartridge capacity is on the way. In Fishers, new lines, customer validations, and contract manufacturing capabilities aim to capture U.S. onshoring demand and support high-value production at scale.

Engineering Segment Underperformance Weighs on Results

Engineering revenue fell 23% in Q4 to EUR 39.4 million, with segment gross margin sliding to 15.8% and operating margin to 9.1%. The company now expects Engineering revenue to decline mid-single to low double digits in 2026, reflecting prior weak order intake and slower conversion of opportunities.

Order Conversion Delays Temper Engineering Outlook

Despite operational improvements, including a doubling of site acceptance rates in 2025, converting pipeline opportunities into firm orders has lagged expectations. This slower sales conversion is prompting a cautious stance on near-term Engineering performance, even as the broader demand backdrop looks constructive.

FX and Tariffs Create Ongoing Headwinds

Foreign exchange was a drag on 2025 results and is expected to remain a factor in 2026, with management modeling an EUR 18 million headwind for the year, including about EUR 10 million in Q1. Tariffs created an additional EUR 4 million headwind in 2025 and remain a structural risk to margins.

Capacity Constraints and Ramp Timing Risks

Demand for cartridges and other high-value products has exceeded earlier expectations, forcing incremental capacity build-outs. The Fishers facility is still ramping, and a major device program is expected to move into commercial activity only around late 2026 or early 2027, leaving some near-term demand potentially supply-constrained.

Heavy CapEx and Rising Net Debt Require Discipline

CapEx remained elevated at EUR 294.9 million in 2025, with 2026 guidance of EUR 270–290 million and net spending of EUR 240–260 million after customer contributions. The company ended 2025 with EUR 130.6 million in cash and net debt of EUR 337.7 million, underscoring the need for continued free cash flow discipline.

Higher Depreciation to Partially Offset Margin Gains

Management warned that depreciation will increase in 2026 as recent growth investments flow through the income statement. This non-cash expense will partially offset the benefits of richer product mix and operational improvements, muting some of the expected margin expansion.

Guidance Underscores Confidence in 2026 Trajectory

For 2026, Stevanato guided revenue to EUR 1.260–1.290 billion, or EUR 1.278–1.308 billion at constant currency, implying around 7.5% reported growth and about 8.3% at constant currency. Management expects adjusted EBITDA of EUR 331.8–346.9 million, adjusted EPS of EUR 0.59–0.63, modest consolidated margin expansion, BDS growth in the high single to low double digits, Engineering declines, and high-value solutions rising to 47%–48% of revenue.

Stevanato’s earnings call painted a picture of a company leaning into high-growth, high-value niches while working through pockets of weakness and execution risk. For investors, the story hinges on sustained biopharma and GLP‑1 momentum, successful capacity ramps, and the ability to translate heavy investment into durable cash generation and margin gains.